BHVN Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Biohaven's net margin of 8.48%. Biohaven's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

Biohaven has a consensus price target of --, signalling upside risk potential of 80.05%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Biohaven has higher upside potential than Eli Lilly and, analysts believe Biohaven is more attractive than Eli Lilly and.

Biohaven has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Biohaven has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Biohaven pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biohaven quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Biohaven's net income of -$160.3M is lower than Eli Lilly and's net income of $970.3M. Notably, Biohaven's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven is -- versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Biohaven's net margin of 36.03%. Biohaven's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Biohaven has a consensus price target of --, signalling upside risk potential of 80.05%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 50.04%. Given that Biohaven has higher upside potential than Regeneron Pharmaceuticals, analysts believe Biohaven is more attractive than Regeneron Pharmaceuticals.

Biohaven has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Biohaven has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Biohaven quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Biohaven's net income of -$160.3M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Biohaven's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven is -- versus 5.83x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Scholar Rock Holding has a net margin of -- compared to Biohaven's net margin of --. Biohaven's return on equity of -- beat Scholar Rock Holding's return on equity of --.

Biohaven has a consensus price target of --, signalling upside risk potential of 80.05%. On the other hand Scholar Rock Holding has an analysts' consensus of $46.38 which suggests that it could grow by 3.52%. Given that Biohaven has higher upside potential than Scholar Rock Holding, analysts believe Biohaven is more attractive than Scholar Rock Holding.

Biohaven has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Scholar Rock Holding has a beta of 0.578, suggesting its less volatile than the S&P 500 by 42.249%.

Biohaven has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven pays -- of its earnings as a dividend. Scholar Rock Holding pays out -- of its earnings as a dividend.

Biohaven quarterly revenues are --, which are smaller than Scholar Rock Holding quarterly revenues of --. Biohaven's net income of -$160.3M is lower than Scholar Rock Holding's net income of -$64.5M. Notably, Biohaven's price-to-earnings ratio is -- while Scholar Rock Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven is -- versus 90.64x for Scholar Rock Holding. Usually stocks with elevated PS ratios are considered overvalued.

Veru has a net margin of -- compared to Biohaven's net margin of -128.15%. Biohaven's return on equity of -- beat Veru's return on equity of -101.38%.

Biohaven has a consensus price target of --, signalling upside risk potential of 80.05%. On the other hand Veru has an analysts' consensus of $3.40 which suggests that it could grow by 429.6%. Given that Veru has higher upside potential than Biohaven, analysts believe Veru is more attractive than Biohaven.

Biohaven has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Veru has a beta of -0.500, suggesting its less volatile than the S&P 500 by 150.04%.

Biohaven has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veru offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven pays -- of its earnings as a dividend. Veru pays out -- of its earnings as a dividend.

Biohaven quarterly revenues are --, which are smaller than Veru quarterly revenues of $6.7M. Biohaven's net income of -$160.3M is lower than Veru's net income of -$8.5M. Notably, Biohaven's price-to-earnings ratio is -- while Veru's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven is -- versus 5.13x for Veru. Usually stocks with elevated PS ratios are considered overvalued.